Seraseq Circulating Tumor DNA v2 Reference Materials

SeraCare Life Sciences has launched a new set of ctDNA reference materials to aid development and validation of liquid biopsy assays. The new Seraseq Circulating Tumor DNA v2 reference materials were produced using a unique technology that produces a DNA fragment size-distribution which closely mimics native cfDNA, while decreasing DNA damage relative to ultrasonicated material, the company said.

The new product requires no special workflow considerations to generate informative data, and contains 40 somatic mutations, including important targets like BRAF V600E, KRAS G12D, and various EGFR alterations. Variants are present against a single well-characterized genomic background across a range of allele frequencies down to 0.125 percent, which ensures utility for assays with different limits of detection.